Objective: Patients with non-small cell lung cancer (NSCLC) with metastases to ipsilateral mediastinal lymph nodes (N2) are an heterogeneous group of patients as regard to prognosis and treatment. Indication and timing of surgery remain controversial. The present study investigates the prognostic factors, in order to identify homogenous subgroups of patients. Methods: Histologically proven N2-NSCLC patients, who underwent a complete surgical resection were retrospectively reviewed. Clinical and pathological features were reported and analyzed, and survival study was performed. Results: One hundred eighty-three patients were analyzed. Overall 1.3 and 5 years survival rates were, respectively, 70, 35 and 20%, with a median survival time of 24 months. Univariate analysis showed a significant better prognosis for: incidental N2 respect to clinical N2 (5-years 35.4 vs 17.4%); single level lymph node involvement respect to multiple levels (5-years 23.8 vs 14.7%); metastases to superior mediastinal or aortic nodes respect to lower mediastinal nodes (5-years 32 and 24.3 vs 16.3%); right upper lobe tumors with superior mediastinal nodes and left upper lobe tumors with aortic nodes respect to lower lobes tumors with lower mediastinal nodes (5-years 31.8 and 26.9 vs 15.7%). Skip metastases had not a significant survival advantage respect to continuous lymphatic spread. N2 clinical status, the number of levels involved and the two specific patterns of lymphatic spread resulted significant prognostic factors at multivariate analysis. Conclusions: Clinical N2 status, number of lymph nodes levels involved and specific patterns of lymphatic spread identify homogenous subgroups of patients that can be proposed for different therapeutic strategies.
Introduction
Metastasis to the ipsilateral mediastinal lymph nodes (N2) is the most important prognostic factor in completely resected non-small cell lung cancer (NSCLC). However, resectable N2-NSCLC represents an heterogeneous group of patients; survival rates after surgical treatment range from 6 to 35% [1] . The appearance in literature in the middle 1990s of two randomized trial reporting a survival benefit of neoadjuvant chemotherapy for N2-NSCLC patients led to change surgical indications for stage IIIA-N2 patients [2, 3] . This new approach became more controversial when another randomized trial failed to reveal a significant advantage for preoperative chemotherapy [4] . Moreover, the International Adjuvant Lung Cancer Trial Collaborative Group has recently reported the results of a large randomized trial showing a significant improvement of survival with cisplatin-based adjuvant chemotherapy in completely resected non-small cell lung cancer [5] . To date, the effectiveness and the optimal timing of surgical treatment of resectable N2-NSCLC remain controversial. In order to identify patients that could benefit of different therapeutic strategies, it is important to define homogeneous subgroups of patients according to prognosis. Several prognostic factors in resected N2-NSCLC have been reviewed [1] and different classifications have been proposed [6] [7] [8] . The aim of this study is to retrospectively analyze the 10-years experience of surgical treatment of N2-NSCLC at our institution, in order to identify the significant clinical and pathological prognostic factors, with particular regard to lymph nodes related features.
Materials and methods
We retrospectively reviewed the patients with hystologically proven N2 non-small cell lung cancer (pN2 NSCLC) who underwent resection with a curative intent, at the Division of and bone scintigraphy were performed only in symptomatic patients. Mediastinal lymph nodes with a short-axis diameter of 1 cm or more at CT scan evaluation were considered abnormal. Mediastinoscopy was performed only when lymph nodes were abnormal on CT scan. Patients with normal mediastinum on CT and those with abnormal mediastinum but negative mediastinoscopy were considered to have N0-N1 disease. Because only pathological N2 tumors were selected for the study, patients with clinical N0 or N1 (cN0-N1) tumors were considered as having an 'incidental N2' disease. Patients with abnormal mediastinum on CT and those with positive medistinoscopy were classified as having clinically N2 disease (cN2).
Complete resection was defined as removal of the primary tumor and all accessible hilar and mediastinal lymph nodes, with no residual tumor left behind (resection of all macroscopic tumor and resection margins free of tumor at microscopic analysis). All patients underwent standard resections (lobectomy, bilobectomy or pneumonectomy). Patients who underwent minor resections were excluded from the study. A complete mediastinal lymph nodes dissection was routinely performed. The following lymph nodes compartments were routinely dissected: superior mediastinal and paratracheal on the right side; aortico-pulmonary window and pre-aortic on the left side, subcarinal and lower mediastinal on both sides. Left paratracheal nodes were not routinely included in the dissection. Only palpable lymph nodes in this region were surgically removed when encountered. For each patient the number of mediastinal lymph nodes resected was recorded. Skip metastases were considered as the presence of mediastinal lymph nodes metastases without intralobar, scissural or hilar lymph node involvement (N2 without N1).
All patients were postsurgically staged according to the 1997-TNM classification [9] . Lymph nodes levels were classified according to the American Thoracic Society system [10] .
In order to evaluate the prognostic impact of N2-related factors we proceeded as follows: Adjuvant chemotherapy with cisplatin-based regimens were administered in the whole cohort in different Oncologic Institutes. Since 1996 induction chemotherapy was considered a viable option at our institute, but not routinely performed. To avoid selection bias and to make the whole cohort more homogeneous, patients who underwent induction chemotherapy were excluded from the study.
Follow-up: most patients have been followed up directly at our Institution, with periodic office visits. Information about the remaining patients was obtained from the Oncologic Institutes, which the patients were referred to or by telephone interviews with the patient and/or his/her relatives. Data regarding long-term survival were recorded.
Statistical analysis: the descriptive analysis was expressed in terms of frequency, mean and standard deviation. Frequencies were compared with the chi-square test for categorical variables; Fischer's exact test was used for small samples; phi correlation index was reported when a significant difference was found. T-test and ANOVA were performed when comparing continuous variables. The probability of survival was calculated according to the Kaplan-Meier method; when creating survival curves, deaths for causes other than the tumor and postoperative deaths were considered as withdrawals, the date of death representing the end-point of follow-up. Univariate analysis of survival was performed using the log-rank test. The main prognostic factors were matched in a multivariate analysis, using Cox regression models. Five years survival rates were selected as end point for evaluating the prognosis. A probability value !0.05 was considered statistically significant.
Results
One hundred and eighty-three patients with pN2 NSCLC who undergone complete resection entered the study. Patients treated with induction chemotherapy were excluded. Characteristics of the 183 patients are listed in Table 1 . Mean age was 63.3 years (median 64, standard deviation 8.8, range 36-84).
A mean of 12.3 mediastinal lymph nodes were resected for each patient (median 11, standard deviation 5.9, range 7-37). Pathways of lymphatic metastases are reported, respectively, in Table 2 . Right upper or middle lobe tumors most frequently spread to superior mediastinal lymph nodes, right lower lobe tumors to lower lymph nodes, left upper lobe tumors to aortic lymph nodes and lower left tumors to all compartments. Skip metastases were recorded in 63 patients (34%). They were more frequently encountered for tumors in the right upper or middle lobe: RUL/RML 29 patients (46%), RLL 11 patients (17%), LUL 9 patients (14%), LLL 14 patients (23%).
Matching all the clinico-pathological and N2-related variables, we found no associations among them, except from the followings: cN0-N1 is more frequently single than cN2 (74 vs 55%, PZ0.01, phi 0.20); adenocarcinoma presented with multiple levels N2 metastases more often than squamous cell carcinoma (66 vs 48%, PZ0.018, phi 0.181); pneumonectomies were performed more frequently for patients with aortic or superior lymph nodes metastases respect to patients with lower levels involvement (39 and 31 vs 8%, PZ0.013, phi 0.183); skip metastases were more frequent in squamous cell carcinoma than in adenocarcinoma (55 vs 44%, PZ0.009, phi 0.198) and in greatest tumors (81% for O3 cm vs 20% for !3 cm, PZ0.039, phi 0.162).
Analysis of survival
There were three postoperative deaths (1.6%): two ARDS following pneumonectomies, an acute myocardial infarction following inferior bilobectomy. All patients were followed up until death, for a minimum of 5 years.
The results of univariate analysis, respectively, for clinical, pathological and lymph nodes related features are reported in Tables 3 and 4 .
No differences in survival were found regarding age, sex, smoking history, type of resection, tumor endoscopy, tumor location, histologic type and grading, pT status, tumor size.
We also performed a univariate analysis of survival for N-clinical status stratified for N2-levels. Four groups were 1. A significant better prognosis was found for cN0-N1 respect to cN2 (Fig. 1 ). 2. Involvement of a single N2 levels had a better prognosis than multiple N2 levels (Fig. 2) 3. Lower lymph nodes had negative prognostic impact respect to superior and aortic stations. 4. RUL/RML with superior nodes and LUL with aortic nodes were patterns of metastases related to a better prognosis than lower lobes with lower nodes (Fig. 3) .
The presence of skip metastases did not significantly improve survival respect to continuous lymphatic spread.
All the clinico-pathological features described above were matched in a multivariate analysis. N status, the number of levels involved and the patterns of metastases were confirmed as significant prognostic factors; for N2 topography a trend toward poorer survival for lower levels was recorded (Table 5) . MST, median survival time. 
Discussion
Patients with operable N2-NSCLC represent an heterogeneous group of patients as regard prognosis and treatment. Many clinical prognostic factors have been investigated [1] . The clinical N2 status and number of metastatic lymph nodes levels were recognized by several authors as significant prognostic factors [11] [12] [13] [14] [15] [16] . These large evidences have led some authors to use these criteria to identify homogenous subgroups of N2-NSCLC patients [6, 7] . In particular, Andre and coauthors [8] in a large multinstitutional study, defined two homogeneous subgroups of N2 patients, on the basis of clinical N status and number of N2 levels involved by metastases. The presence of a single station-incidental N2 (cN0-N1) depicts a subgroup with a good prognosis, with survival results close to stage IIB. On the contrary, the preoperative finding of N2 in multiple levels is related to a very poor prognosis, similar to stage IIIB. Also in our series incidental N2 and the number of N2 levels involved resulted as significant prognostic factors, either as single variables or when combined.
Some authors have demonstrated the prognostic influence of the relation between primary tumor location and N2 levels involved [17] [18] [19] . Patients with RUL tumors with ipsilateral level 4 lymph nodes have better survival compared with patient with RUL tumors and metastases to level 7 [17] . Patients with LUL tumors and metastases to level 5 and 6 have survival similar to N1 patients [18, 19] . In our study, three patterns of lymph nodes metastases influenced survival. Patients with right upper lobe tumors and lymphatic metastases to superior mediastinal nodes showed acceptable survival after complete surgical resection, as well as patients with left upper lobe tumors and lymphatic metastases to aortic nodes. On the contrary, lower lobe tumors with lymphatic metastases to subcarinal, esophageal and pulmonary ligament nodes represent metastatic patterns related to very poor prognosis. The pattern of lymphatic spread related to tumor location represents a more important prognostic factor respect to node topography alone (superior and aortic versus lower stations) as demonstrated in multivariate analysis, where node topography does not reach statistical significance in affecting survival.
As recently reported [19] , a classification of N2-NSCLC should consider number of lymph node levels involved and pattern of metastases, as well as clinical N2 status. For cN0-N1/single station and for upper lobe tumors with superior or aortic lymph nodes levels, a complete surgical resection with lymph node dissection can be proposed as first treatment. These patients are ideal candidates for randomized trials of adjuvant therapies. Clinical N2 with multiple stations and lower lobes tumors with metastases to lower lymph nodes should not be considered for initial surgery and induction chemotherapy is advisable. Techniques of mediastinal staging play a central role. At present, it is widely accepted to use mediastinoscopy in patients with mediastinal lymph nodes enlargement at CT scan. The usefulness of systematic mediastinoscopy is still debated.
Giving the prognostic importance of lymph nodes levels not accessible to traditional mediastinoscopy, other invasive techniques ought to be considered in mediastinal staging. Videothoracoscopy may play an important role, because it can sample suspected lymph nodes in multiple stations, in particular at aortic and lower levels, not accessible to mediastinoscopy. The effectiveness of videothoracoscopy in the preoperative staging of NSCLC has already been addressed [20] . Its routine use should be considered in patients with NSCLC and lymph nodes enlargement in multiple stations at CT scan.
The different therapeutic strategies that can be proposed to different N2 groups underline the importance of a complete mediastinal lymph node dissection, although a survival advantage of mediastinal lymph node dissection over systematic sampling is not clearly demonstrated [21] [22] [23] [24] . The high number of resected lymph nodes for each patient in our series reflects the extensive lymph node dissection we performed.
Skip metastates are thought to derive from subpleural lymphatics that drain directly to the mediastinum. Even if some evidences suggest an increased survival for skip metastases, its prognostic role remains unclear. [23] [24] [25] . Pranzel et al. correlated this survival advantage for patients with skip metastasis to an higher expression of antiapoptosis gene BCL2 and lower expression of p21 respect to patients with sequential N1-N2 lymphatic spread [24] . Otherwise, other authors failed to find difference in survival between skip metastases and continuous spread [25] . In our series, we found skip metastases in 34% of surgically resected N2-NSCLC, which is similar to what is reported in literature. As previously reported by other authors [24, 25] , we confirmed that skip metastases were more frequently associated to squamous cell carcinoma than to other histologic subtypes. Though a trend was present in our study, a survival advantage for skip metastases compared to continuous pathways of lymphatic spread was not recorded. To date the prognostic role of skip metastases remains controversial. Further studies are needed.
In conclusion, the intraoperative detection of previously undiagnosed mediastinal lymph nodes metastases (incidental N2), the number of mediastinal lymph nodes levels involved by the tumor and specific patterns of lymphatic spread to mediastinal nodes are significant prognostic factors. They are useful to classify N2-NSCLC patients into homogeneous groups. These different subtypes of patients are ideal candidates for further randomized clinical trial regarding the timing of surgery in relation to chemotherapy. 
